Can Cannabis Be Used In The Treatment Of Alzheimer’s Disease?

Cannabis has not been established as a treatment that prevents, cures, or slows Alzheimer’s disease. Some cannabinoid medicines are being studied for agitation, a distressing behavioral symptom, and several trials offer useful but mixed evidence. Improving agitation is different from preserving memory or changing the course of the disease.

For families considering cannabis, the most useful questions are which symptom needs treatment, which exact preparation has been studied, and whether potential relief outweighs adverse effects for that person. A retail oil or edible is not interchangeable with a medicine used in a controlled trial.

Laboratory Findings Do Not Establish a Treatment

Research on cannabinoids and the endocannabinoid system explores processes relevant to Alzheimer’s, including inflammation and amyloid-related changes. Experiments in cells and animals can identify research targets, but cannot demonstrate that a cannabis product removes harmful proteins or restores lost brain function in people.

The Alzheimer Society of Canada cautions against claims that cannabis treats or prevents Alzheimer’s disease. Newer symptom trials need to be evaluated on their own terms; they do not validate broad claims of neuroprotection.

Dronabinol: A Signal for Agitation, With Limits

A randomized dronabinol trial published in the February 2026 journal issue enrolled 75 participants with Alzheimer’s and clinically significant agitation. It compared a prescribed THC preparation with placebo over three weeks, alongside existing care.

Dronabinol improved one of the two prespecified main agitation outcomes, the Pittsburgh Agitation Scale, significantly more than placebo. The other, the Neuropsychiatric Inventory Clinician agitation/aggression measure, did not reach statistical significance. Somnolence was a notable adverse effect.

This is a promising symptom-specific result, but the short duration and mixed main outcomes limit the conclusion. It does not establish long-term safety, improved memory, or slowed disease progression. The trial’s dosing protocol should not be used as a home dosing guide for cannabis products.

THC/CBD Trials Have Not All Shown Benefit

The 2025 STAND feasibility study randomized 29 care-home residents with probable Alzheimer’s and agitation to nabiximols, a THC/CBD mouth spray, or placebo. Adherence was high and no adverse reactions were reported, but the study was designed primarily to assess feasibility. Its authors called for a larger efficacy trial; successful administration is not proof of effective treatment.

An August 2026 crossover trial randomized 25 residents with severe dementia to THC/CBD oil and placebo in separate eight-week periods; nineteen completed both periods. The oil did not significantly outperform placebo on the main agitation measure or other main behavioral outcomes.

Use of as-needed psychotropic medicines was lower during active treatment, and no serious adverse events related to the study drug were observed. That secondary finding merits further research, but does not turn the negative main agitation result into a proven benefit. The study also included severe dementia rather than establishing an effect in every Alzheimer’s population.

Assess the Cause of Agitation First

Agitation can reflect pain, constipation, poor sleep, overstimulation, changes in routine, or medication effects. The National Institute on Aging recommends looking for triggers and discussing them with the care team. A calm voice, familiar routines, less noise, reassurance, and a suitable activity may help.

A sudden or rapidly fluctuating behavioral change, especially after an infection or medication change, needs immediate medical attention. It should not automatically be treated as ordinary Alzheimer’s progression or managed by adding a sedating product.

Existing Treatments and Safety Considerations

Alzheimer’s care includes established medicines and supportive approaches. Lecanemab and donanemab are options for selected people with early Alzheimer’s; they require specialist assessment and monitoring and do not cure the disease. Their role differs from medicines intended to manage agitation.

In the United States, brexpiprazole has an FDA indication for Alzheimer’s-related agitation. In April 2026, the FDA also approved dextromethorphan-bupropion for that indication. These medicines have their own risks and require individualized prescribing; neither approval establishes a role for cannabis.

THC can affect thinking and alertness, while CBD is not free of adverse effects or interactions. For someone with dementia, the care team should monitor sedation, confusion, walking stability, and changes in daily function as well as the target symptom. A quieter or sleepier person is not necessarily experiencing better well-being.

Questions for the Treating Clinician

Discuss the specific behavior, possible triggers, treatments already tried, and every medicine or supplement being used. If a clinician considers a cannabinoid, agree on a measurable goal, who will administer it, how adverse effects will be tracked, and when an unsuccessful trial will stop. Include the person with dementia in decisions as much as possible, with appropriate support.

Local access rules do not determine medical effectiveness. Cannabis should not replace an Alzheimer’s treatment plan or be presented as a way to reverse the disease.